Open main menu

Psychiatrienet β

Sertraline-clomipramine

Revision as of 20:08, 30 July 2009 by Walter (talk | contribs)
Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from sertraline to clomipramine.[1] [2]

Nietinrijdenbord.png Stop sertraline
  • Day 0: gradually reduce dosage of sertraline to a maximum of 50 mg/day when this dosage is > 50 mg/day.
  • Day 1: reduce dosage of sertraline to a maximum of 25 mg/day.
Eenrichtingbord.png Start clomipramine

Caution is necessary.

  • Day 1: simultaneously start administration of clomipramine in a low dosage of 25-50 mg/day.
  • Day 8: stop administration of sertraline and only continue administration of clomipramine in a dosage of 75 mg/day.
  • Start low, go slow!
Infobord.png More information
  • Sertraline dose-dependently slows the metabolism of clomipramine via CYP2D6.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.